GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (WBO:ZBH) » Definitions » Debt-to-EBITDA
中文

Zimmer Biomet Holdings (WBO:ZBH) Debt-to-EBITDA

: 2.57 (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zimmer Biomet Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €825 Mil. Zimmer Biomet Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4,597 Mil. Zimmer Biomet Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was €2,113 Mil. Zimmer Biomet Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zimmer Biomet Holdings's Debt-to-EBITDA or its related term are showing as below:

WBO:ZBH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.02   Med: 4.88   Max: 9.96
Current: 2.66

During the past 13 years, the highest Debt-to-EBITDA Ratio of Zimmer Biomet Holdings was 9.96. The lowest was 1.02. And the median was 4.88.

WBO:ZBH's Debt-to-EBITDA is ranked worse than
69.63% of 428 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs WBO:ZBH: 2.66

Zimmer Biomet Holdings Debt-to-EBITDA Historical Data

The historical data trend for Zimmer Biomet Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 8.08 4.30 3.93 2.66

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.47 2.62 2.59 2.77 2.57

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Debt-to-EBITDA falls into.



Zimmer Biomet Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zimmer Biomet Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(825.3 + 4596.554) / 2035.923
=2.66

Zimmer Biomet Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(825.3 + 4596.554) / 2112.768
=2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Zimmer Biomet Holdings  (WBO:ZBH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zimmer Biomet Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (WBO:ZBH) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.